Sec. 30617. Longitudinal study on the impact of COVID–19 on recovered patients
346 words·~2 min read·
/bill/116/hr/6800/eh/section-30617A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Part A of title IV of the Public Health Service Act ( 42 U.S.C. 281 et seq.) is amended by adding at the end the following: The Director of NIH, in consultation with the Director of the Centers for Disease Control and Prevention, shall conduct a longitudinal study, over not less than 10 years, on the full impact of SARS–CoV–2 or COVID–19 on infected individuals, including both short-term and long-term health impacts. The Director of NIH shall begin enrolling patients in the study under this section not later than 6 months after the date of enactment of this section.
The study under this section shall— be nationwide; include diversity of enrollees to account for gender, age, race, ethnicity, geography, comorbidities, and underrepresented populations, including pregnant and lactating women; study individuals with COVID–19 who experienced mild symptoms, such individuals who experienced moderate symptoms, and such individuals who experienced severe symptoms; monitor the health outcomes and symptoms of individuals with COVID–19, or who had prenatal exposure to SARS–CoV–2 or COVID–19, including lung capacity and function, and immune response, taking into account any pharmaceutical interventions such individuals may have received; monitor the mental health outcomes of individuals with COVID–19, taking into account any interventions that affected mental health; and monitor individuals enrolled in the study not less frequently than twice per year after the first year of the individual's infection with SARS–CoV–2.
For purposes of carrying out the study under this section, the Director of NIH may develop a network of public-private research partners, provided that all research, including the research carried out through any such partner, is available publicly. The Director of NIH shall make public a summary of findings under this section not less frequently than once every 3 months for the first 2 years of the study, and not less frequently than every 6 months thereafter. Such summaries may include information about how the findings of the study under this section compare with findings from research conducted abroad.
There is authorized to be appropriated to carry out this section $200,000,000, to remain available until expended. .
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 30617
Longitudinal study on the impact of COVID–19 on recovered patients
Cites 1Cited by 0 across 0 sources